Clinical trial
Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
NCT03018080
Study timeline
Study start (actual)2017-06-12Date precision: day
Registry last updated2023-08-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast - Femaleunresolved
Male Breast Cancerunresolved
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
PaclitaxelDRUG · verified · RxNorm: paclitaxel
Sponsors & collaborators
Wake Forest University Health Scienceslead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03018080 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.